Pharmacogenomics

Every person is different.

Your body has a tiny plan inside. This plan tells your body how to work. It also tells your body how to use medicine.

Sometimes, one medicine works well for you. But it might not work for a friend. Doctors can look at your tiny plan. This helps them pick the right medicine. They want to find the best way to help you feel better. This helps avoid medicine that might make you feel sick. It is a way to make medicine just for you.

Have you ever wondered why one medicine works for you, but not for a friend?

The answer may be in your genes.

Scientists study this using pharmacogenomics. This is the study of how your genes affect your response to drugs. Your genes are like a tiny instruction book for your body. They tell your body how to use medicine.

Some genes control enzymes. Enzymes are parts of your body that help break down drugs. Some people have genes that make fast enzymes. Others have genes that make slow enzymes. If enzymes work too fast, the medicine might not work. If they work too slow, the medicine might build up and make you sick.

Genes also control transporters. These are parts that move medicine through your body. Other genes act as drug targets. These are the specific spots where medicine goes to work.

Doctors can use tests to look at your genes. They can use genotyping or sequencing. Sequencing is a way to read your entire genetic code. This helps doctors move away from a "one-size-fits-all" way of giving medicine. They can pick the best treatment just for you. This is called precision medicine.

Have you ever wondered why one medicine works for you but not for a friend?

The answer might be hidden in your DNA. Scientists study this through a field called pharmacogenomics. This science combines pharmacology, the study of drugs, with genomics, the study of genes. It looks at how a person's unique genetic makeup changes how they respond to medicine. Instead of a "one-dose-fits-all" approach, this field helps doctors find the best treatment for each person. This goal is often called precision medicine or personalized medicine.

To understand how this works, we can look at how the body handles a drug. One part is called pharmacokinetics, which is the way the body absorbs, moves, and breaks down medicine. Enzymes in the body act like tiny workers to help with this. Some genes tell the body to make many workers, while others make fewer. If these enzymes work too fast or too slow, the medicine might not work well. It might even become toxic and make a person feel sick.

Another way genes affect medicine is through pharmacodynamics. This is the study of how a drug actually affects the body. Drugs often look for a specific "target" to land on to do their job. Genetic changes can change these targets, making the drug more or less helpful. For example, some cancer medicines only work for patients with specific genetic mutations. Sometimes, drugs hit "off-target" sites by mistake. This can cause problems, like when a person with a certain gene deficiency has a bad reaction to a medicine.

Many important groups of genes and enzymes have been identified by researchers. The cytochrome P450 family is a huge group of enzymes. They are responsible for breaking down 70% to 80% of all medicines used in clinics today. Specific names in this family include CYP3A4, CYP2C9, CYP2C19, and CYP2D6. There are also transporters that move medicine through parts of the body like the blood or the brain. These include the solute carrier and the ATP-binding cassette transporters. Knowing these names helps scientists understand exactly how a drug travels.

Today, there are many ways to use this science to help patients. Doctors can use genotyping or whole genome sequencing to read a person's genetic code. This helps them avoid the "trial-and-error" method of picking medicines. Groups like the Clinical Pharmacogenetics Implementation Consortium (CPIC) create guidelines for doctors to follow. Even the U.S. Food and Drug Administration (FDA) uses this information to help label medicines. By using these tools, doctors can choose treatments that are safer and more effective for everyone.

Pharmacogenomics, often called PGx, is a scientific field that studies how a person's genome affects their response to drugs. The name comes from combining pharmacology, the study of drugs, with genomics, the study of genes. This science examines how both inherited and acquired genetic variations change how a person reacts to medication. By looking at DNA mutations, such as point mutations or copy number variations, researchers can predict how a patient will respond to a treatment. The ultimate goal is to move away from a "one-dose-fits-all" approach to medicine. Instead, scientists aim to develop precision medicine, where treatments are optimized for an individual's unique genetic makeup.

To understand this process, we must look at pharmacokinetics, which describes how the body handles a drug. This involves four main steps: absorption, distribution, metabolism, and elimination. These processes are often managed by enzymes, such as drug metabolizing enzymes, or by drug transporters. Genetic variations in the DNA loci that produce these proteins can change their activity. For example, a person might have an increase, a decrease, or a total loss of function in a specific enzyme. If these proteins do not work correctly, the amount of medication in the body may change. This can cause a drug to fall outside the therapeutic window, leading to either a loss of effectiveness or dangerous toxicity.

Drug-metabolizing enzymes are a critical part of this mechanism. A very important group is the cytochrome P450 enzyme family. This family is responsible for the metabolism of 70% to 80% of all medications used in clinical settings. Within this group, enzymes like CYP3A4, CYP2C9, CYP2C19, and CYP2D6 are highly polymorphic, meaning they vary greatly between people. Other enzymes, such as UGT1A1, DPYD, and TPMT, also play roles in how drugs are processed. Additionally, drug transporters like the solute carrier or ATP-binding cassette help move medications across cellular membranes. These transporters move drugs between body fluid compartments, such as the blood, gut lumen, or the brain.

Pharmacogenomics also explores pharmacodynamics, which is the study of a drug's impact on the body. Drugs often work by interacting with specific drug targets. This interaction can inhibit or potentiate the target's activity. In oncology, many targeted therapeutics are designed to address somatic mutations in these targets. For instance, EGFR inhibitors like gefitinib or erlotinib are only used for patients with specific mutations to the EGFR gene. Genetic changes in these targets can also be germline mutations, which are inherited. A well-known example is the interaction between the drug warfarin and the VKORC1 gene. Warfarin inhibits the VKOR enzyme, which is vital for the vitamin K cycle and blood coagulation.

Sometimes, drugs can have unintended effects at "off-target" sites. This happens when a medication or its metabolites interact with a site other than the intended target. Genetic variation at these off-target sites can cause significant health issues. One notable example involves the enzyme glucose-6-phosphate-dehydrogenase, or G6PD. This enzyme is part of a pathway that helps protect cells from oxidative stress. In people with a G6PD deficiency, cells are more vulnerable to damage. If these individuals take certain medications with oxidative effects, they face a high risk of erythrocyte lysis, which leads to hemolytic anemia.

There is a distinction between pharmacogenetics and pharmacogenomics. While the terms are often used interchangeably, they describe different scopes of study. Pharmacogenetics is limited to monogenic phenotypes, which involve interactions with a single gene. In contrast, pharmacogenomics refers to polygenic drug response phenotypes. This broader field encompasses other scientific areas like transcriptomics, proteomics, and metabolomics. This allows for a much more complex understanding of how many different biological layers work together to influence a person's health and their reaction to a specific chemical compound.

Several organizations work to make this science useful in hospitals. The Clinical Pharmacogenetics Implementation Consortium, or CPIC, is an international group that creates evidence-based guidelines. These guidelines help clinicians understand how to use genetic test results to optimize drug therapy. In the United States, the FDA also provides resources like the Table of Pharmacogenetic Associations. This table helps prescribers identify subgroups of patients who might have altered drug metabolism. Additionally, the NIH-funded PharmGKB resource collects and shares knowledge about how genetic variation affects medication response. These tools help ensure that medicine is safer and more effective for everyone.